BICO Group AB (publ)·Healthcare

BICO Group AB (publ) (BCCOY) Q4 2025 Earnings Call Transcript

BICO Group AB (publ) (OTCMKTS:CLLKF - Get Free Report) saw a significant increase in short interest in January. As of January 15th, there was short interest totaling 11,371 shares, an increase of 74.5% from the December 31st total of 6,516 shares. Based on an average daily trading volume, of 1,975 shares, the short-interest ratio is

BICO Group AB (publ) (OTCMKTS:CLLKF - Get Free Report) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totaling 6,516 shares, an increase of 29.3% from the December 15th total of 5,039 shares. Based on an average daily volume of 155 shares, the days-to-cover
BICO Group AB (publ) operates as a bio convergence company in North America, Europe, Asia, and internationally. It operates through two segments, Laboratory Solutions and Bioautomation. The Laboratory Solutions segment offers 3D bioprinters, hybrid microscopes, single-cell dispensing instruments, and liquid handling instruments, as well as services and related consumables, such as bioinks, reagents, microscope lenses, software, printheads, and 3D reconstructed human tissues for applications in regulatory testing. This segment also offers services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology to pharmaceutical and biotechnology companies. The Bioautomation segment offers products in precision dispensing and biosensor technology to the industrial customer; and diagnostics automation and advanced robotics solutions for the medical and diagnostic industries. In addition, it offers core industrial ecosystem, tissue engineering, multi-omics, cell line development, and diagnostics solutions. It primarily serves medical, pharmaceutical, and cosmetic industries. The company was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. BICO Group AB (publ) was founded in 2016 and is based in Gothenburg, Sweden.